Strategic partnerships, product innovation, and commercial expansion fuel Unlearn’s growth and lay the foundation for 2025
In 2024, Unlearn® achieved key milestones in advancing AI to eliminate trial and error in medicine. From securing $50M in Series C funding to launching innovative tools and forming strategic partnerships, Unlearn made significant progress in addressing challenges like slow enrollment, long timelines, and high costs in clinical research.
$50M Series C Funding Fuels Commercial Expansion and Product Growth
Unlearn secured $50M in Series C funding, bringing its total funding to over $130M. Led by Altimeter Capital with participation from returning investors, including Radical Ventures and Mubadala Capital, this investment drives Unlearn’s commercial growth by expanding its customer-facing teams, enhancing product engineering capabilities, and delivering AI-powered solutions to a broader network of pharmaceutical and biotech partners. Additionally, the funding supports advancements in Unlearn’s machine learning models, Digital Twin Generators (DTGs), which are the foundation for the company’s innovative clinical trial solutions.
TrialPioneer: AI Tools for Smarter Trial Design
In 2024, Unlearn launched TrialPioneer, a free web-based application enabling pharmaceutical and biotech teams to collaborate and understand how trial design decisions impact sample size requirements, power, and enrollment timelines, demonstrating the advantages of AI-optimized trial designs over traditional approaches.
Strategic Partnerships Advance Neurological Clinical Development
Unlearn collaborated with leading organizations to address critical challenges in neurological research:
- At the Alzheimer’s Association International Conference (AAIC), Unlearn presented with AbbVie and Johnson & Johnson Innovative Medicine, demonstrating how digital twins of trial participants can reduce control arm sizes and increase power in Alzheimer’s disease clinical trials.
- In partnership with ProJenX, Unlearn’s participants’ digital twins will be integrated into the Phase 1 trial of prosetin (PRO-101), with plans to evaluate critical ALS outcomes such as ALSFRS-R and plasma neurofilament light in a 52-week open-label extension.
- A collaboration with German-based APST Research will incorporate data in APST’s longitudinal ALS study, significantly strengthening the ALS DTG’s performance in creating precise digital twins of ALS patients, while supporting the design of more efficient clinical trials.
A New Era of Commercial Growth
To support its commercial expansion, Unlearn appointed Steve Herne as CEO, while Charles Fisher transitioned to serve on Unlearn’s board. This leadership change positions Unlearn to scale its product offerings and continue delivering AI solutions that redefine clinical development.
“2024 has been a year of tremendous growth and achievement for Unlearn,” said Herne. “We’re excited to build on this momentum in 2025 and beyond, continuing to drive innovation that delivers meaningful impact for researchers, sponsors, and patients alike.”
About Unlearn
Unlearn is an AI company transforming clinical trials with digital twins of patients. Trusted by leading global pharmaceutical companies, the Unlearn Platform provides an intuitive interface that puts the power of AI in sponsors' hands. Unlearn’s EMA-qualified method aligns with current FDA guidance for phase 3 trials, offering innovative and actionable solutions to optimize clinical development.
For more information, visit www.unlearn.ai or follow us on LinkedIn and X/Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212800371/en/
Contacts
Alyssa Horowitz
unlearn@pancomm.com
